• Yakup Arslan, Deniz Dogan, Nesrin Ocal, Alperen Koc, Tunahan Ayaz, Recep Ozkan, Fatma Yoruk, Meltem Nilsen Esmer, Sumeyye Kosger, Ekin Kadioglu, Umit Savasci, Ferhat Cuce, Gonca Fidan, Gulden Yilmaz, Neslihan Kayahan Satis, Sedat Bilge, Serkan Senkal, Canturk Tasci, and Hakan Kayir.
• Department of Chest Diseases, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.
• Int. J. Clin. Pract. 2021 Sep 1; 75 (9): e14461.

ObjectiveCoronavirus disease 2019 (COVID-19) is an emerging, fast-spreading, highly mortal and worldwide infectious disease. The pulmonary system was defined as the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mortality concept of this disease presented with more severe and systemic disease. The present study investigated the relationship between the patient characteristics at the initial hospital administration and fatality in COVID-19 patients.MethodsIn this retrospective and comparative cohort study, all the 767 hospitalised COVID-19 patients, treated between 18 March and 15 May 2020 in the Covid Clinics of Gulhane Training and Research Hospital in Ankara, Turkey, were evaluated.ResultsThe fatality rate was significantly increased in patients with any comorbid disease except asthma. The initial laboratory test results indicated highly significant differences according to the patient's outcome. A multifactor logistic regression analysis was performed to calculate the adjusted odds ratios for predicting patient outcomes. Being older than 60 years increased the death risk with an adjusted OR of 7.2 (95% CI: 2.23-23.51; P = .001). The presence of a cancer and the extended duration of intensive care unit treatment were other significant risk factors for nonsurvival. Azithromycin treatment was determined as significantly reduced the death ratio in these patients (P = .002).ConclusionIt was revealed that being older than 60 years, presence of a cancer and extended duration of ICU treatment were the major risk factors for predicting fatality rate in hospitalised COVID-19 patients.© 2021 John Wiley & Sons Ltd.

14 keywords...

hide…